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7An unequivocal evidence base shows that harm reduction 
works. In countries all around the world, implementing and 
scaling up harm reduction interventions such as needle and 
syringe programmes and the provision of opioid substitution 
therapy has been shown to prevent infections, save lives and 
to reduce crime.[1, 2] Importantly in the current financial climate, 
harm reduction approaches are also proven to be both cost-
effective and cost-saving for those governments that invest in 
them.[3, 4] Supportive evidence for the effectiveness and cost-
effectiveness of take-home naloxone programmes[5] and drug 
consumption rooms[6] is also clear from those countries where 
they are in place, leading several governments to consider 
adding these approaches to their national harm reduction 
programmes in recent years. 
Europe is the birthplace of harm reduction and is the region 
where the successes of this approach in averting and reducing 
HIV epidemics among people who inject drugs can be most 
plainly seen. However, even in some of these long-term 
implementing countries where harm reduction is integrated 
into national health systems, economic crises and political 
pressure have affected the provision and reach of services. In 
other countries, harm reduction funding has been severely cut, 
resulting in sharp increases in HIV infections among people 
who inject drugs. In others still, where international donor 
funds have ended or dramatically reduced, some governments 
have increased domestic support for harm reduction, but a 
notable few have not. In these worst cases, harm reduction 
services have been left in a state of emergency.
This report will present the findings of Harm Reduction 
International’s research into harm reduction investment 
in EU member states, structured around four key areas: 
harm reduction coverage; government investment in harm 
reduction; transparency of spending data; and civil society 
representatives’ views on sustainability of funding. Compiled by 
HRI, the findings are based on contributions from civil society 
across the region and address the successes and challenges 
faced in ensuring sustainable harm reduction responses in EU 
member states.
Methodology:a  
HRI collaborated with researchers in seven EU countries 
(Czech Republic, Greece, Italy, Estonia, Portugal, Hungary 
and Lithuania) to gather data on national investment in key 
harm reduction interventions, to compile survey responses 
in consultation with key stakeholders and to complete a case 
study on harm reduction funding in their respective countries.b 
Within the report these countries are highlighted as case study 
countries. In the remaining EU member states, HRI approached 
civil society contacts with an online survey,c initially providing 
a three-week window for responses to be submitted via 
SurveyMonkey. Most contacts were members of the European 
Harm Reduction Network (EuroHRN) and/or the Eurasian Harm 
Reduction Network (EHRN) and had some involvement in both 
harm reduction service provision and national or regional 
advocacy. 
Limitations: 
Unfortunately, HRI received no survey responses from Austria, 
Denmark, French Belgium, Latvia, Luxembourg, Slovakia, 
Slovenia, Spain or Romania, despite additional time being given 
and reassurance that as a new area of study for most, data 
gaps were to be expected and any insights would be useful. 
In the case of Romania, however, there was enough data 
available from existing sources to provide a picture of the harm 
reduction funding situation without a survey response. The 
limited response rate is likely to be indicative of time limitations 
facing overburdened harm reduction service providers, as well 
as unfamiliarity with the subject matter leaving some reluctant 
to respond. Several contacts indicated that while this was an 
important area of study for them, they did not have access 
to the right information or did not have the time to spare to 
gather information. Therefore, the report cannot provide a 
complete picture of the harm reduction funding situation 
with the European Union. However, there are many valuable 
insights into the challenges and successes for sustainable 
harm reduction funding in those countries included in the 
report. 
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a  For full details on the research methodology please refer to the HRI website: www.hri.global/harmreductionworks.
b  For national case studies please refer to the HRI website: www.hri.global/harmreductionworks.
c  HRI was unable to identify contacts to send the survey to in Croatia, Cyprus and Malta. In Belgium, the survey was sent to two contacts, representing Flemish and French Belgium respectively.
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Guide to country ranking system: 
HRI developed a simple set of criteria to categorise the harm 
reduction funding situations in EU member states (see Table 
1). Based on research undertaken within the Harm Reduction 
Works! project, countries have been grouped using a traffic 
light system as either red, amber or green on each criterion. 
This traffic light system is useful to provide an at-a-glance 
indication of the health of harm reduction funding in a country. 
However, detailed justifications of each ranking decision should 
be referred to for further insight into the national context.d  
Within the report, country information will be presented using 
the four criteria below as sub-headings, starting with those 
countries categorised as mainly red and ending with those 
mainly green.
d  It should be noted that ranking decisions, particularly where researchers were not employed to carry out in-depth research, were somewhat dependent on individual respondents’ proximity to 
the relevant subject matter and available data. Harm reduction coverage information for each country is summarised in a short table. For more detailed analysis of coverage with full references, 
please refer to HRI’s website: www.hri.global/harmreductionworks/.
Table 1: Criteria for establishing national harm reduction funding situation 
Factor Green Amber Red 
Harm reduction 
coverage
Both NSP and OST operating 
at recommended coverage 
levels
Either NSP or OST operating 
at recommended coverage 
levels
Neither NSP or OST operating 
at recommended coverage 
levels
Transparency of 
spending data
Spending information 
routinely collected and made 
available in a transparent 
manner
Partial spending information 
available
Spending information 
unavailable
Government investment 
in harm reduction
Overall government 
investment is high and 
government provides over 
90% of harm reduction 
funding
Government investment 
is moderate, either 
proportionally (e.g. 
government provides 
between 50% - 90% of HR 
funding) or as an overall 
amount
Government investment is 
low, either proportionally (e.g. 
government provides less 
than 50% of harm reduction 
funding) or as an overall 
amount
Civil society 
representatives’ view on 
sustainability of funding 
Funding judged to be secure 
for next 5 years
Some uncertainty around 
funding levels and anticipated 
reductions in the next five 
years
Funding for harm reduction 
extremely low, or serious 
funding cuts anticipated in the 
next five years
9There is a funding crisis for harm reduction within the 
European Union, albeit a crisis confined to specific states. 
Bulgaria, Romania, Poland, Greece and Hungary are ranked 
red on two or more criteria within this report, indicating a poor 
state of funding for harm reduction. The findings highlighted 
three factors that underpin their situations; namely austerity, 
international donor retreat and poor political support for 
harm reduction. These factors of course overlap and interact 
with each other. In Bulgaria and Romania, where until recently 
harm reduction had been predominantly supported through 
international donor funding, the investment gap left behind 
and the absence of increased government support to cover 
this has crippled service provision. 
Since the international financial crisis in 2008, the majority of 
European governments have imposed austerity measures. 
There is evidence of these measures having a detrimental 
effect on harm reduction funding in Greece, where national 
investment in OST in 2015 is half the level of investment at 
its peak in 2012. Even in Portugal, where harm reduction 
has political support, the government has preserved existing 
harm reduction investment to the same levels, but has not 
increased it to reflect the impact of austerity in increasing 
living costs. This has resulted in a streamlining of services and 
an overburdening of harm reduction workers. Elsewhere, the 
impact of austerity has been buffered somewhat, particularly 
in those countries where political will for harm reduction is 
strong.
The European Union is home to some of the best examples 
of sustainable harm reduction funding, including several 
states that enjoy well-funded politically supported harm 
reduction programmes that were ranked mostly green within 
this research. However, the situation in some EU states is 
as challenging as in other parts of the world. In general, the 
state of harm reduction funding is better in countries in the 
Western part of the European Union, but this is not uniform. 
Greece for example faces significant funding challenges. 
There are also examples of good practice from the East, such 
as Estonia and the Czech Republic. Findings from Belgium, 
Finland, France, Germany and the Netherlands all highlighted 
good practices and strategies that could be useful to inform 
change in other parts of the region. Some common factors 
that tend to be in place in these countries include political 
support for harm reduction as a practical, effective and cost-
effective approach, supportive laws and policies for harm 
reduction and strong and supported civil society. Importantly, 
the political support came not just from national government, 
but also decision-makers at regional and municipality levels, 
which yielded significant investments in service delivery. It 
was in these countries where a wider spectrum of harm 
reduction interventions were financially supported by national 
governments including drug consumption rooms, heroin-
assisted treatment and take home naloxone programmes. 
However, even in these countries, this research highlighted 
gaps and areas where governments could improve the 
efficiency of their investments. To do this effectively, however, a 
clear understanding of current investment is necessary.
No country achieved a green ranking on transparency of 
harm reduction spending. Even in countries with well-funded 
harm reduction programmes that were achieving high 
coverage, it was challenging for civil society representatives 
and researchers to establish the level of harm reduction 
investment with any level of accuracy. While some countries 
had carried out dedicated research on this in the context of 
wider drug policy expenditure, this was not routine and did 
not reach down to the level of intervention. Some countries 
had national mechanisms in place to track certain health 
or drug policy-related expenditure but did not isolate harm 
reduction spending. Commonly, the spending related to the 
provision of OST was the most difficult to extricate from wider 
health care provision spending, as this service was integrated 
into the national health systems and was delivered alongside 
numerous other services in an outpatient healthcare setting. 
In several countries the harm reduction funding allocations 
were devolved to the regional or municipal level, which 
resulted in wide variation in funding levels across the country. 
Where there was no mechanism for centrally tracking regional 
investment and aggregating this, the process of establishing a 
national picture of harm reduction funding in these countries 
was, as our researcher in Italy described, ‘truly detective 
work’.[7] 
This knowledge gap on harm reduction funding threatens the 
ability of governments to ensure the success of their national 
programmes. It should not be so challenging to establish what 
is being spent on crucial harm reduction interventions. This is 
necessary information for strategic budget decision making to 
ensure that ever-reducing funding is invested where it is most 
needed and will have the most impact. This project provided 
an important opportunity for harm reduction advocates in 
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seven countries to study harm reduction investment in a more 
in-depth fashion than they had been able to before. This has 
informed national advocacy efforts and it has initiated dialogue 
between civil society and decision-makers on improvements 
that could be made to the current funding situation in several 
countries. 
‘This study allowed several stakeholders to 
understand that there is a real possibility to 
enhance the total amount of money available 
for harm reduction very considerably if dialogue 
between funders and harm reduction projects gets 
improved. This type of work is now beginning to 
take place.’ - Marta Pinto, Harm Reduction Works! 
researcher, Portugal 
According to the findings of this research, the future 
sustainability of harm reduction funding in Europe ranges 
from fairly certain to extremely insecure. Civil society in 
several countries shared fears that rapid increases in HIV 
infection rates among people who inject drugs were likely or 
even imminent due to limited harm reduction and, in some 
cases, a rise in amphetamine use and associated increased 
injecting. In the Czech Republic, oral methamphetamine 
capsules are being distributed to give people an alternative 
to injecting methamphetamine. Elsewhere, it was reported 
that harm reduction services traditionally oriented towards 
people who inject opioids were being required to adapt their 
services to new drug use trends. In several places, civil society 
representatives lamented that this adaptive flexibility was not 
possible due to limited funding and already stretched service 
providers. This research highlights several actions that could 
increase the sustainability of harm reduction funding within the 
European Union.
11
National authorities
1. At the 2016 UN General Assembly Special Session on 
Drugs, all EU member states committed to reducing 
the adverse public health and social consequences of 
drug use, endorsing four harm reduction interventions 
– “medication-assisted therapy, injecting equipment 
programmes and antiretroviral treatment”, alongside 
Naloxone for the treatment of overdose. The previous year 
they also committed to ending AIDS by 2030 under target 
3.3 of the UN Sustainable Development Goals. In order to 
fulfil these international obligations, national governments 
must ensure sustainable funding for harm reduction. 
2. Moreover, under international human rights law, states 
should not take deliberately retrogressive measures that 
deprive people of rights they previously enjoyed, including 
reducing health spending or cutting health services. This 
applies to countries that are reducing budgets through 
austerity measures. With both increased drug use and HIV 
incidence reported in Europe during periods of economic 
hardship,[8] governments should ensure that harm 
reduction funding is not reduced to the extent where this 
has an impact on service provision. Indeed, in the cases of 
Greece and Romania, the European Monitoring Centre on 
Drugs and Drug Addiction (EMCDDA) has explicitly advised 
the respective governments to protect harm reduction 
funding from austerity measures.[9] 
3. Also in the context of austerity, governments should 
undertake cost-effectiveness studies into their drug policy 
spending and redirect funds from drug enforcement 
to harm reduction. Across the region, investment in 
ineffective and often repressive drug enforcement 
measures dramatically outweighs spending on health 
and harm reduction. Data modelling by Harm Reduction 
International and the Burnett Institute has shown that 
a redirection of 7.5% of funds globally would have the 
potential to virtually end AIDS among people who inject 
drugs by 2030.[10] 
4. Finally, the knowledge gap on harm reduction funding 
threatens governments’ ability to ensure success. It 
is extremely challenging to establish current harm 
reduction spending levels in European countries, where 
harm reduction is often heavily integrated into health 
systems. National authorities should make harm reduction 
spending information more transparent and should 
systematically monitor it in order to inform budget 
allocations and to ensure the efficiency of investment. 
Options to integrate indicators on harm reduction 
spending into existing monitoring mechanisms should be 
explored. 
These recommendations echo the recent Malta Declaration 
on HIV/AIDS, which called on EU member states to “ensure 
high-impact, evidence-based and cost-effective combination 
prevention measures targeting priority groups including … 
effective, comprehensive and accessible harm reduction 
services for people who use drugs and their sexual 
partners”.[11]
The European institutions
1. This research highlighted that five EU countries - Bulgaria, 
Greece, Romania, Hungary and Poland - are experiencing 
funding crises for harm reduction. Most of these countries 
are now ineligible for Global Fund grants, or will soon 
become ineligible, while domestic investment is low and 
rates of injecting drug use, HIV and hepatitis C are high, 
or increasing. The European Commission should create a 
time-bound emergency fund to keep services in operation 
in such countries to avert public health emergencies.  
2. With civil society organisations (CSOs) being the sole 
providers of harm reduction in a number of these 
countries, the European Commission should ensure 
that any future emergency fund be accessible to CSOs 
and avoid cumbersome application processes with very 
low success rates.[12] One suggestion would be a grant 
distribution and management system modelled on that 
used by the Norway NGO Fund grants (EEA) where local 
civil society plays a key role in managing the grants.[13] 
Any emergency harm reduction grants should also be 
exempt from the European Union standard co-funding 
expectations.
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3. Beyond emergency funding, the European Commission 
should lead the development of a new HIV Strategy and 
Action Plan with a strong emphasis on ensuring the 
sustainability of harm reduction services. The next EU 
Action Plan on Drugs, to cover the period 2017-2020, 
should support these efforts. The Directorate Generals of 
Health and Justice need to collaborate more effectively to 
ensure a sustainable harm reduction response within the 
EU. 
4. Finally, as the European monitoring body on the Drugs, 
the EMCDDA and its network of National Reitox Focal 
Points should consider including specific indicators 
on harm reduction investment within regular data 
collection requirements. This could be the mechanism to 
systematically track spending and to flag any changes in a 
timely manner to alert the European Commission that a 
country may require outside assistance to avoid a public 
health emergency. 
5. Once again these recommendations echo The Malta 
Declaration on HIV/AIDS which invites the European 
Commission to use the EU Health Programme to help 
support public health measures required to be taken 
by Member States, and urges them to provide political 
support and financing for global and regional efforts to 
end AIDS by 2030.
The Global Fund for AIDS, TB and Malaria
1. The Global Fund for AIDS, TB and Malaria must do more 
to support and encourage governments in those EU 
states where it is withdrawing harm reduction funding to 
transition to national funding. Responsible transition is 
paramount to the sustainability of harm reduction (and 
other) programmes, particularly where there is limited 
political support.
2. The Global Fund’s NGO rule, which provides for directly 
funding NGOs in upper-middle income countries that 
fit the Global Fund’s eligibility criteria, must remain an 
option for countries where government investment 
in programmes is not forthcoming. Applications from 
civil society organisations in Hungary and Bulgaria have 
been declined on the basis that there was not enough 
proof of political barriers to funding harm reduction. 
The Global Fund should better define what is meant by 
political barriers and what constitutes proof that these are 
insurmountable enough to warrant Global Fund support.
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Table 2: Harm reduction funding in the European Union at a glance
Country Harm reduction coverage
Transparency of 
spending data
Government 
investment in harm 
reduction
Civil society view on the 
sustainability of funding
Bulgaria
Romania
Poland 
Hungary 
Greece
Lithuania
Italy 
Sweden
Czech Republic
Portugal 
Finland 
Estonia
UK
Ireland not known
Belgium
France
Germany
The Netherlands
Harm reduction international RepoRts14
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Transparency of spending data
Information on current investment in harm reduction 
interventions in Bulgaria is not made public.[14] Attempts to 
establish the actual spending on OST, for example, have 
proved challenging. In-depth research would be required 
to establish the total national investment in harm reduction 
as, while some spending reports are likely to be held by the 
Ministry of Health and the Global Fund, this information is not 
accessible or likely to be disaggregated by intervention.
Government investment in harm reduction
The Bulgarian government funds approximately 73% of the 
national HIV response, including covering the cost of HIV 
testing and treatment.[12] They also partially fund the provision 
of OST, covering the cost of about one-third of OST clients in 
the country.[15] These treatment slots have long waiting lists 
and are primarily filled by people living with HIV and pregnant 
women.[15] The remaining two-thirds of OST clients partially 
or wholly pay for their own treatment with the costs varying 
depending on the provider. As the free and less expensive 
treatment slots are often full, providers can charge a premium 
for this treatment. Two-thirds of people receiving OST in the 
country pay a monthly fee amounting to at least one-third of 
the minimum national wage. Those receiving buprenorphine 
and a small number receiving Substitol also pay for their 
medication costs.[12] 
Since 2003, harm reduction programmes have been primarily 
supported through a Global Fund grant to the Bulgarian 
Ministry of Health for the ‘Prevention and Control of HIV/AIDS’. 
While technically still eligible for Global Fund funds under the 
NGO rule,e  in 2014, the Global Fund did not allocate HIV funds 
to Bulgaria as they judged the evidence of political barriers 
to implementing HIV prevention activities to be insufficient.
[12] A no-cost extension was granted until May 2017, allowing 
previously unspent funds to be used, after which Bulgaria’s 
Global Fund HIV grant will be due to close. It is hoped that 
harm reduction programmes will then be funded by the 
government, although there has been no confirmation of this 
to date. 
Decreasing international assistance for the HIV response in 
Bulgaria has been met with increased investment from the 
Bulgarian government. In 2013, domestic support was almost 
three times that of the international support (USD 8.7 million 
versus USD 3.1 million respectively).[16] However, the gap that 
the Global Fund’s departure is leaving for harm reduction 
funding has not been covered by the government. NSP, peer 
education and outreach will be amongst the interventions most 
affected by this reduction in funding. Civil society organisations 
report that cuts in Global Fund support in late 2015 led two 
of the ten NSPs to cease operations. Of the remaining eight 
programmes, six have been able to continue their services 
until May 2017.[15] NGO Iniciativa za Zdrave estimate that the 
budget required to keep NSPs operating at 2014 levels is about 
USD 425,000, just 5% of total government investment in the 
national HIV response.[15] While harm reduction is within the 
national strategy, this political commitment in writing has not 
yet been met with finances.[15] There remains no clear plan 
for a transition from international donor support to a state-
supported national harm reduction programme.[15] 
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Bulgaria - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 19,000
NSP Low coverage – 10 sites delivered the equivalent of 59 syringes per person injecting drugs in 2013.
OST Low coverage – 3,563 clients receiving OST (mainly methadone) in 2013
DCR Not available
Prison harm reduction OST is available in one prison in Sofia for those receiving OST prior to incarceration. No NSP available
Take home naloxone No take-home naloxone programmes
e  The NGO rule allows NGOs in countries with political barriers to service provision to apply for Global Fund funding without approval of the County Coordinating Mechanism.
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Civil society view on sustainability of funding
In 2014, the threat of Global Fund departure galvanised civil 
society action, with collective lobbying, press conferences, 
parliamentary actions and a manifesto signed by over 30 NGOs 
to fight for HIV prevention activities to continue. 
When asked how harm reduction services could be made 
sustainable in the future, civil society organisations pointed 
to the Bulgarian Health Act, which states that 1% of the 
government tax on alcohol and cigarette sales should be used 
to fund prevention programmes relating to tobacco, alcohol 
and drugs. Currently, this funding is managed by Ministry 
of Finance but it is not clear where funds are invested. Civil 
society have been calling for this tax to be directed towards 
harm reduction programmes and it is believed that the amount 
available would be substantial enough to cover the gap left by 
international donor retreat.[15] 
In 2016, harm reduction advocates report that the low 
prioritisation of harm reduction by the Bulgarian government 
continues to be the primary barrier to the continuation of 
harm reduction in Bulgaria. If this remains the case, domestic 
support is unlikely to cover the gap left behind by the exiting 
Global Fund. 
As recommended by the Eurasian Harm Reduction Network in 
2015, the development of a clear and realistic plan to transition 
from international donor funding to state support for harm 
reduction is essential. EHRN suggest that the Ministry of Health 
should work with the Global Fund to establish the transition 
plan, ensuring civil society engagement and integration with 
the new National Program for Prevention and Control of HIV/
AIDS and STI 2016-2020. They also emphasise the need to 
ensure NGO funding mechanisms are working optimally, and 
to garner cross-ministerial support for harm reduction.[12] 
Until such a plan exists and can be implemented, the Global 
Fund should reconsider the case of Bulgaria and deem the 
country eligible for HIV funding under the NGO rule.f This 
would ensure that harm reduction services can continue and 
that the gains made with Global Fund support over the past 
decade are not lost.
f  For more details on the NGO rule, see the Global Fund Eligibility List 2017 available here: https://www.theglobalfund.org/media/5601/core_eligiblecountries2017_list_en.pdf and the Global Fund 
Eligibility Policy available here: https://www.theglobalfund.org/media/4227/bm35_06-eligibility_policy_en.pdf
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Transparency of spending data
Establishing current spending on harm reduction in Romania 
is challenging as this data is not routinely collected or 
made public. In the Eurasian Harm Reduction Network’s 
recent analysis of the country’s readiness to transition to 
a state-funded response, they note ‘The government has 
not undertaken a costing of each component of the harm 
reduction program and data from NGOs is sporadic and not 
recognized by the Government.’[17]
Government investment in harm reduction
Harm reduction in Romania has been predominantly funded 
by international donor assistance. Global Fund support for 
the national HIV response in Romania ended in 2010. With 
no transition plan in place, this resulted in a collapse of NSP 
services in particular and a sharp increase in HIV infection 
among people who inject drugs followed.[17-19] Since 2010, 
various funding sources have supported harm reduction 
services, including structural funding from the European 
Union allocated to harm reduction services between 2011 and 
2014.[17] Additionally from 2014-2016, the Ministry of Health 
received funding from the Norwegian Financial Mechanism 
to strengthen HIV, hepatitis B and C prevention which also 
supported NSP delivery. A Global Fund TB grant managed by 
Romanian Angel Appeal runs from 2015-2017 and includes 
some support for harm reduction. This grant has led to 
improved outreach and TB integration into the remaining NSP 
services in Bucharest. 
While committed in policy through the new National Strategy 
on Narcotics 2013-2020 and associated Action Plan 2013-
2016,[20] there is no budget attached to this work and, overall, 
the government has provided little financial support for harm 
reduction. Following protest action in 2013, the Ministry of 
Health provided some financial support to NSP for a limited 
period. The National anti-Drug Agency did also procure needles 
and syringes but there are reports that these were of such 
poor quality that people refused to use them until no others 
were available.[21] In recent years, the Bucharest municipality 
has supported ARAS to deliver NSP but this funding has been 
limited and not sufficient to cover all costs.[22] In real terms, 
government investment in harm reduction has been minimal. It 
is estimated that less than 1% of the Government’s HIV budget 
goes towards HIV prevention,[23] when UNAIDS recommends 
this should amount to 25% for an effective national HIV 
programme.
 Sustainability of harm reduction funding 
Harm reduction in Romania has been under serious threat 
since the Global Fund’s departure in 2010. There followed a 
spike in HIV infections among people who inject drugs which 
caused international concern and civil society action. This 
galvanised some government investment, but the majority 
of support came from external donors, briefly leading to an 
increase in harm reduction service coverage. But in 2016, 
service coverage had decreased again, leading civil society 
organisations to warn of the likelihood of more rapid increases 
in HIV among people who inject drugs. 
Romania - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 19,265
NSP Likely low coverage – 2 NSP in 5 fixed locations in Bucharest
OST Low coverage – 2014 estimates ranging from 8.8% to 19.4% of people use opiates receiving OST
DCR Not available
Prison harm reduction In theory NSP in 8 prisons but programme not functional
Take home naloxone No take-home naloxone programmes
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In November 2016, Romanian civil society organisations issued 
a joint statement to the Global Fund Board in advance of the 
Thirty-Sixth Meeting calling for the country’s eligibility for HIV 
funding under the “NGO rule”g to be considered and urging the 
Board to prevent Romania being allocated no funds for the HIV 
component for the period 2017-2019.h
Romanian NGOs are in theory eligible to apply for Global 
Fund funding for HIV under the “NGO rule”, but evidence of 
political barriers to service delivery was deemed insufficient 
by the Global Fund Board. The Eurasian Harm Reduction 
Network recently assessed Romania’s readiness to transition 
from international donor assistance to state support using 
their Transition Readiness Assessment Tool. Romania scored 
31% indicating a low level of preparedness, particularly in 
the areas of governance and finance. They highlighted that 
‘no sustainability plan has been drafted; no institutionalised 
governance mechanism for the HIV/AIDS sector is envisaged; 
and there is no formal mechanism by which NGOs can 
receive government funding’. They concluded that there is 
no government willingness to invest in harm reduction at this 
time.[17]
g  The NGO rule allows NGOs in countries no longer eligible for a Global Fund grant to apply for funds when there are considerable barriers to funds being provided by the government. 
h  See full text of the letter and list of signatories here: http://drogriporter.hu/en/romania_letter; more info here: http://www.harm-reduction.org/blog/romania-and-other-middle-income-countries-
%E2%80%93-lost-transition-and-lack-solidarity
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Transparency of spending data
There is no mechanism for easily identifying harm reduction 
expenditure in Poland. Harm reduction allocations are made 
both at the national level by the National Bureau for Drug 
Prevention (NBDP) and at the provincial level by municipalities. 
To establish the amount invested in harm reduction provision 
in Poland would require dedicated research. 
There was an effort made to estimate the funding for NGOs 
with drug demand reduction programmes in 2012, including 
harm reduction.[25] Then in 2013, data was collected from 
municipal governments on their drug-related expenditure.[25] 
However, these processes did not isolate harm reduction costs 
within them so they do not provide insight into harm reduction 
spending. 
Government investment in harm reduction
The government is the main source of harm reduction funding 
in Poland. Civil society representatives could not estimate 
expenditure on NSP in Poland. At the national level, the 
NBDP holds a budget for prevention, harm reduction and 
rehabilitation. In 2014, the NBDP allocated around €170,000 
for harm reduction programmes, some of which supported 
NSP.[26, 27] However, civil society state that very often these 
funds are directed towards programmes prioritising clients 
becoming abstinent.[27] There is also funding from the Ministry 
of Health for the National AIDS Centre, but this does not 
currently support harm reduction programmes or other drug-
related initiatives. 
At the local level, the main city within each province can 
allocate funds from their municipal budgets to harm reduction 
initiatives. The extent to which harm reduction receives funds 
at the municipal level is determined by the local government 
support for harm reduction approaches, but as this is not 
tracked, it is difficult to know what levels of funding are in 
place in each Polish county. EMCDDA report that the NBDP 
co-financed twelve projects for people who use drugs, while 
local governments contributed to the funding of eighteen harm 
reduction programmes.[25] Funding for safer nightlife initiatives 
is available but is most often spent on drug prevention 
programmes, rather than harm reduction.[27] 
The provision of OST is fully funded by the National 
Government Health Fund. The most recent spending data 
suggests that in 2012, the government invested around 
€4,750,000 in OST provision. 
EMCDDA report an estimate of public drug-related expenditure 
to have been €25,805,008 in 2014, based on spending data 
from NGOs and local government. This represents 0.01% of 
gross domestic product (GDP) in Poland.[25] Harm reduction 
spending is likely a small proportion of this figure, as it would 
also include drug prevention initiatives, abstinence-based 
programmes and more. It is also reported that the overall 
amount invested in drug-related initiatives is likely to have 
decreased in recent years.[25, 27]
 
Poland - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 15,119 (10,444–19,794) 
NSP Low coverage – 167,119 syringes distributed in 2014[24]
OST Low coverage – in 2014, there were 2,586 clients receiving OST
DCR Not available
Prison harm reduction Limited OST provision in 23 prisons with 140 prisoners receiving OST in 2014
Take home naloxone No take-home naloxone programmes
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Sustainability of harm reduction funding 
While there are no accurate estimates of NSP funding in 
Poland, it is reported that service provision has decreased due 
to reduced funding in recent years.[25, 27] Harm reduction is 
included in The National Programme for Counteracting Drug 
Addiction, which is a part of the National Health Programme 
2016-2020 accepted in 2016 by the government. Harm 
reduction receives greater emphasis in this document than 
in the previous plan which ran from 2011 – 2016, with the 
interventions of NSP and OST explicitly named.
Civil society reports that harm reduction funding is likely to 
be secure in the near future, as it is explicitly included within 
national plans. However, it is not clear whether this investment 
will be increased, remain at current levels, or whether it may 
be harder for harm reduction programmes to access funds in 
the future. As in some other countries within the EU, funding 
derived from gambling profits has been allocated towards 
drug related programmes in the past. The National Bureau for 
Drug Prevention manages these funds, which have supported 
harm reduction programmes previously. Ultimately, however, 
it is the political support for harm reduction approaches 
at government level that will determine the future of harm 
reduction investment in Poland.  
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Transparency of spending data
There is no mechanism currently tracking harm reduction 
investment in Hungary. As in many other countries, it is 
challenging to isolate this from other drug and health service 
expenditure. For this project, data was gathered directly from 
service providers to establish a picture of national spending. 
This was time-intensive and had its limitations as not all service 
providers could share their spending records. Some were 
reluctant to be fully transparent about grants they received 
to supplement their funding from the government for fear 
of jeopardising their access to funds in the future. While this 
research provided some insight into the national investment 
in harm reduction, these limitations render accurate routine 
tracking of harm reduction extremely challenging at the level of 
individual NGOs or institutions.[13]
Government investment in harm reduction
The vast majority of funding for harm reduction comes from 
the central national budget of the Government, with a small 
proportion from local, private and international sources. 
There are two major government sources of funding for 
NGOs providing harm reduction services. The first is the basic 
operational grant which provides a fixed annual amount 
of about €24,000. NGOs can apply for one grant per year 
regardless of their reach or scope of services they provide. This 
is not sufficient to cover operational costs for the larger service 
providers, so they are required to supplement this funding with 
other money. Some do so through other government health 
and social care grants and some through European Union 
structural funds aimed at improving employment, ‘recovery’ or 
other interventions.[13]
The second source of government funding is the KAB-FF 
tenders, under the heading of “Supporting the recovery of 
addicts”, which are distributed by the Ministry of Human 
Resources. This funding covers a wide range of services 
for people who currently and previously used drugs. Harm 
reduction service providers are eligible to apply under two 
funding categories; low threshold services and OST. In 2012-
2014, of 58 organisations receiving funds, 29 included NSP 
among their services.[13] 
The following estimates of government investment in harm 
reduction have been calculated through Harm Reduction 
Works! Research. However, given the multiple limitations in 
gathering this information they must be viewed as indicative 
best estimates rather than as a wholly accurate representation 
of national spending. In 2014, it is estimated that €456,093 
was spent on the provision of needle and syringe programmes, 
via 19 service out of 30 service providers in the country.i 
Approximately 92.4% of this spending was covered by 
government funds.[13] In 2014, the MAC AIDS Foundation gave 
a small grant of around €16,000 to the NGO Blue Point, the 
organisation that operated the largest NSP in 2014.[13] 
OST provision is primarily funded through the National Health 
Insurance Fund of Hungary. In 2014, it is estimated that 
€774,930 was spent on OST provision, wholly by government 
funds.j
Case study country 
Hungary - A snapshot of harm reduction funding 
Research undertaken by Peter Sarosi and Robert Csák
Harm reduction coverage
People who inject drugs 2,910 - 3,577
NSP Low coverage – 30 sites with NSP distribution equating to 28 syringes per person injecting drugs in 2014
OST Low coverage – up to 20% of the opiate using population receive OST
DCR Not available
Prison harm reduction No prison-based harm reduction programmes are available
Take home naloxone No take-home naloxone programmes
i  These 19 service providers were responsible for 96% of the total NSP provision in Hungary in 2014. 
j  This was calculated by estimating the cost of provision of methadone maintenance treatment at 330,000 HUF per client and the cost of buprenorphine-naloxone treatment at 370,000 HUF per 
client. This included the cost of medication and the working hours of public health professionals. This method was determined the most accurate by the national researchers after approaching 
each service provider for spending data yielded only partial information.
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In addition, the largest safer nightlife service provider INDIT has 
an annual budget of around €25,800 per year, which includes 
state funding and a small grant for activities at an annual 
festival from the festival organisers. 
There is some evidence to suggest that people who use drugs 
also invest in their own harm reduction. Researchers report 
that there is a black market for sterile injecting equipment 
with syringes sold for between €0.32-1.61 depending on 
how difficult they are to access in the area. While some OST 
providers do prescribe buprenorphine-naloxone (Suboxone) 
for free, several OST clients have to purchase this in 
pharmacies because it is not fully covered by health insurance. 
Researchers estimate that this is, however, a small proportion 
of those receiving the treatment in the country.[13] 
Sustainability of harm reduction funding 
Harm reduction funding is considered to be under threat in 
Hungary by national civil society groups. Following austerity 
measures and a change of government in 2010, the funding 
situation for harm reduction in Hungary declined. A new drug 
strategy was adopted which deprioritised harm reduction and 
included a goal for Hungary to become drug-free by 2020. 
This had an immediate impact on funding for harm reduction. 
Labelled budget lines for harm reduction were removed from 
the annual requests for tenders from the Ministry of Social 
Affairs and Labour and the total available amount was reduced 
from €2.6 million to €1.3 million. This caused harm reduction 
NGOs to compete with recovery organizations for a reduced 
amount of funding. NGOs were also only permitted to receive 
one grant each, further limiting the accessibility of funds. Civil 
society made efforts to advocate for an improved funding 
system which would allow funding to be proportionate to 
programme size, but these funding restrictions eventually led 
to the closure of the two largest NSP providers in 2014. Overall, 
civil society reports that harm reduction funding is increasingly 
insecure in Hungary, with no clarity on which NGOs can expect 
funding in the long-term and most left uncertain about the 
possibility of grant extensions until they are due.
Among people attending NSP, the injecting of new 
psychoactive substances (NPS) tripled in Hungary between 
2011 and 2015, when it was found that 80% of all clients were 
injecting NPS. Within this group, it was also found that hepatitis 
C prevalence had doubled and that sharing of syringes and 
other injecting equipment was significantly higher than among 
other people injecting drugs.[28] Researchers and civil society 
warn that these factors are contributing to increases in blood-
borne infections among people who inject drugs and that 
public health emergencies are likely.[29] 
While there is an innovative initiative to fund drug treatment 
programmes through a gambling industry tax, the funds will 
not be directed towards harm reduction initiatives.[13] 
This research found that in 2014, the total 
estimated national spending on harm 
reductionk in Hungary amounted to just €1.26 
million. By contrast, researchers estimated 
expenditure on punitive drug law enforcement 
in the same year to be approximately €2 
billion, almost 2,000 times the amount spent 
on harm reduction.[13] l If a tiny proportion 
of this expenditure was redirected to harm 
reduction this would transform harm reduction 
programmes in the country and save countless 
lives. 
  
 
k  Here encompassing NSP, OST and safer nightlife programmes. 
l  This was estimated by calculating the total spend on police, justice system, incarceration divided by the percent of drug related crimes compared to the number of total registered crimes in 
Hungary.
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Transparency of spending data
While the Greek Reitox National Focal Point for the EMCDDA 
has gathered some information on drug policy expenditure, 
this has not been routinely collected and the data have not 
been disaggregated in a manner that allows harm reduction 
spending to be easily identified. 
With no central repository of this information, establishing 
national harm reduction investment requires analysis of the 
annual spending records of each harm reduction service 
provider in Greece. This is the approach that was taken within 
this project and several limitations were apparent. Aside from 
being time-consuming, it was also challenging to gather a 
full picture of national spending as some service providers 
were not willing or able to be fully transparent about their 
spending. Harm reduction interventions are often delivered 
alongside other services and their specific costs not labelled 
within spending records. There is no standardised method of 
recording programme expenditure, which makes it challenging 
to compare spending across providers and come up with 
meaningful national estimates of harm reduction spending. 
The information gathered therefore represents best estimates 
of spending and must be considered with caution. 
Government investment in harm reduction
The National Reitox Focal Point to the EMCDDA estimated 
NSP expenditure in 2014 to have amounted to €2,529,901. 
This included expenditure of the main harm reduction service 
providers that included NSP within their activities.[30] The Greek 
agency against drugs “OKANA” is the main NSP provider in 
Greece, responsible for approximately 78% of NSP service 
provision in the country. In 2014, OKANA spent an estimated 
€1,476,000 on NSP provision.[30, 31] This investment covered 
the operation of low threshold harm reduction programmes 
and included NSP, condom distribution, medical services and 
day centres operating mainly in Athens and Thessaloniki. 
Approximately 80% of this investment was covered by the 
State Budget with funding from the Ministry of Health and the 
remaining 20% from contributions of the European National 
Strategic Reference Framework (ENSRF) programmes and 
Greek private donations.[30] 
In 2014, an estimated €23,259,784 was invested in OST 
provision in Greece.[30] OKANA is the exclusive provider of OST 
in the country and this service is wholly funded by national 
government investment. In 2015, national investment in OST 
reduced to €18,931,361 which covered OST delivery at 54 sites.
[31] National OST investment has been decreasing since its peak 
in 2012, when €38,416,939 was spent on OST delivery. This 
latest decrease equates to spending being halved between 
2012 and 2015. It is reported that this has affected the quality 
of services, led to significant understaffing and reduced 
salaries. An additional €119,812 went towards two OST sites 
within prisons.[31] 
Case study country 
Greece - A snapshot of harm reduction funding 
Research undertaken by Fivos Papamalis
Harm reduction coverage
People who inject drugs 5,120 (4,209 - 6,303)
NSP Low coverage – 16 sites delivered the equivalent of 70 syringes per person injecting drugs in 2014
OST High coverage – 8,426 people were receiving OST in 2014
DCR Not available
Prison harm reduction OST is available in two prisons and in 2014, only 80 people were receiving OST within prison. No NSP available
Take home naloxone No take-home naloxone programmes
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Although there are no official estimates of the out-of-pocket 
harm reduction spending of people who use drugs, there is 
evidence to suggest that many people do pay for their own 
harm reduction. Methadone and buprenorphine are sold on 
the black market, with prices ranging from €20-50 for 60mg 
methadone and €6-15 for 8mg suboxone/subotex. While 
pharmacies can sell needles and syringes, many pharmacists 
in Athens will not sell these to people they suspect of injecting 
drug use. As a result, people buy injecting equipment from the 
streets, sometimes at five times the pharmacy sale price (€0.20 
per syringe from pharmacies versus €1 street price).
Sustainability of harm reduction funding 
Following the rapid increase in HIV among people who inject 
drugs in 2011, the government invested in the increase of 
harm reduction in Greece, by establishing a coordinated 
harm reduction response which saw the reduction in HIV 
infection among people who inject drugs in the following 
years. However, there is concern that the gains made could 
now be lost, as public austerity measures have negatively 
affected harm reduction funding to the point where this has 
begun to significantly reduce. The contribution of European 
and international donor funds has now also reduced and 
cannot be considered a sustainable source of funding for harm 
reduction in Greece. As recommended by the EMCDDA, the 
Greek authorities should consider provisionally excluding harm 
reduction programmes from public spending cuts to protect 
people who inject drugs and to avoid another public health 
emergency. 
In recent years, there has been an increasing emphasis on 
punitive drug policy implementation in Greece, including 
increasing drug-related arrests, forced medical examinations 
and preventing access to harm reduction services.[30] It is 
recommended that a cost-benefit analysis of drug policy 
spending is conducted to ensure that government spending on 
punitive drug law enforcement does not further undermine the 
potential for harm reduction in Greece. This will also facilitate 
the Greek authorities to implement evidence based resource 
relocation of public drug expenditure and invest in effective 
and cost-effective interventions. 
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Transparency of spending data
In Lithuania, no spending information related to harm 
reduction is collected at the national level. There is some 
information on budget allocations (which can differ 
dramatically from actual spending) available but these are 
within programmatic documents or institutional budgets 
and figures are inconsistent methodologically and difficult to 
compare. There is also a reluctance to share information from 
the National Centre for Communicative Diseases and AIDS and 
the Prisons Department under the Ministry of Justice, which 
poses challenges to establishing an accurate picture of the 
situation.[32] 
Research carried out by the “I Can Live Coalition” in the context 
of a Global Fund regional grant held by the Eurasian Harm 
Reduction Network has already gathered detailed information 
on the funding situation in Lithuania. It is only for this reason 
that estimates on NSP and OST were readily available 
and simply required updating, rather than additional data 
gathering.
Government investment in harm reduction
NSP in Lithuania is supported by funding from the national 
government budget (45%), from municipal government 
budgets (49%) and from one international donor (American 
Health Foundation) (6%).[32] There are no available spending 
records isolating NSP investment, so for this research a 
calculation was made based on the average cost of NSP 
delivery per client, multiplied by the estimated number of 
regular NSP clients. When based on the average cost for client 
multiplied by the official estimate of regular NSP clients,m 
the estimate of spending in 2014 was about €306,190. 
However, the “I Can Live Coalition” found discrepancies in the 
official estimate of regular clients which suggested this to be 
somewhat inflated.[33] Therefore, to determine a more accurate 
representation of spending, the average cost per client was 
multiplied by an estimate of the number of regular clients 
that had been extrapolated from the estimates of 2012 and 
2013, which seemed appropriate given that there had been 
no funding or service provision increase since this time. This 
produced a spending estimate for NSP in 2014 of between 
€150,000 and €160,000. Through Harm Reduction Works! 
research, financial data from nine out of eleven NSP sites in 
the country was gathered which suggested this estimate to be 
more accurate.[32] 
The cost of OST provision is solely covered by national 
government funds, with the exception of buprenorphine, 
which is provided at a cost to the client. For this research, it 
was estimated that government spending in 2014 equated 
to €333,602. This calculation is based on the average cost of 
OST provision per client multiplied by the number of people 
receiving OST on December 31st, 2014, including those in 
detention centres. As buprenorphine is provided at a cost 
to a client this is not reflected in the estimate. According to 
studies carried out by the “I Can Live Coalition”, at least a 
four-fold increase in funding is needed in order to reach the 
recommended coverage of 40% of the estimated people 
who inject drugs in Lithuania with an optimal package of OST 
services.[33] 
Case study country 
Lithuania - A snapshot of harm reduction funding 
Research undertaken by Jurga Poskeviciute
Harm reduction coverage
People who inject drugs 6,056
NSP Low coverage. 9 sites regularly and 2 sites occasionally provide NSP 
OST Low coverage. 19 sites with clients receiving buprenorphine or methadone
DCR Not available
Prison harm reduction Not available, although OST can be continued in detention centres under the Ministry of Internal Affairs for those already receiving it
Take home naloxone In 2016, the Vilnius Centre for Addictive Disorders began providing naloxone to people upon release from in-patient detox programmes
m  Attending services at least once a month in the last 12 months. 
Harm reduction international RepoRts26
No international funding sources had existed for OST in 
Lithuania since the UNODC project “HIV/AIDS prevention 
and care among injecting drug users and in prison setting in 
Estonia, Latvia and Lithuania” finished in 2011. With the end of 
this project, the number of OST patients dropped in 2011 and 
again in 2013.[32]
Until 2016, funding for OST has been allocated in two ways 
– direct allocations to drug dependence treatment clinics 
through the National Program for Treatment of Dependencies 
and through partial allocations of the National Health 
Insurance Fund. Starting in 2016, all treatment services 
are reimbursed by the Fund to clinics based on the actual 
number of services provided. Usually budget ceilings exist 
in the annual budget of the National Health Insurance Fund, 
but overspending can be covered periodically from reserve 
funds.[32] 
Funding allocations for NSP from the national government 
budget are guided by the National Drug Control and 
Prevention Program that is developed every few years, in 
conjunction with an Inter-institutional Action Plan, including 
annual allocations for specific actions. These allocations 
are reviewed by each implementing institution each year, 
so the Action Plan can be modified annually. This allocation 
is distributed through an annual grant competition for a 
maximum amount of €6,000 each to non-budgetary funded 
organisations (usually 2-3 NGOs will receive funds this way, 
but there are only one or two more that would be eligible). The 
money remaining from the grant competition is then used to 
buy NSP supplies and distribute to all sites based on the need 
that the sites identify.
Municipalities that fund NSP also allocate funding annually 
through various municipal programmes such as health 
or social affairs. This is a completely separate process to 
national government funding allocations for NSP. Of all the 
municipalities, one provides four-year budget allocations for 
NSP, providing more security for the longer term provision of 
services.[32]
While there are no available estimates of government 
expenditure on drug law enforcement and punitive drug 
policy measures, this investment is given higher priority over 
health and harm reduction measures. Recent changes in the 
Administrative Code will leave sanctions for possession of 
small amounts of illicit substances purely a matter of Criminal 
Code, which the “I Can Live Coalition” warns will mean more 
criminalisation for drug possession, when many countries are 
moving away from this approach.[32]
Sustainability of harm reduction funding 
It is likely that the government has the capacity and political 
will to sustain harm reduction funding at current levels for 
the next five years. There is already a significant funding 
gap for harm reduction in Lithuania, however, so increased 
funding is necessary. The “I Can Live Coalition” estimate that 
bringing coverage levels up to UN standards would require a 
six-fold increase in funding for NSP and a four-fold increase 
in funding for OST. Currently, NSP sites are regularly subject 
to supply shortages and have periods of funding gaps which 
mean they run the risk of closure. The services they provide 
are not deemed extensive enough (for example they do not 
offer hepatitis C testing, overdose prevention or linkage to HIV 
services and there is limited outreach) and the hours that they 
currently open are very limited. In addition, there is a need 
for services tailored towards women and people who inject 
amphetamines. There are not enough OST sites across the 
country, the quality of service provision outside Vilnius requires 
improvement and OST programmes should be initiated within 
prisons under the Ministry of Justice.[32] 
Harm reduction funding in Lithuania has been decreasing since 
2011, following the end of a UNODC grant. The government 
did not intervene to support the programmes that UNODC had 
been funding and the number of both OST and NSP clients has 
been steadily dropping each year, while at least two NSP sites 
have stopped providing services altogether. Further research 
is necessary to determine the impact of this on the health of 
people who inject drugs in Lithuania. There are plans by the 
Ministry of Health for investments into new OST and NSP sites 
from EU structural funds (which cover infrastructure costs only) 
that could potentially be used to expand the current coverage 
and scope of services. There is now also a plan for OST in 
prisons to become available under the Ministry of Justice, 
following much civil society advocacy on the issue to show that 
there were no legal or other barriers to offering this service. 
This is particularly urgent given a recent significant rise in new 
HIV cases within prisons in 2016.[32]
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To increase the sustainability of funding for harm reduction in 
Lithuania, there would need to be clear institutional leadership, 
support and oversight for harm reduction service provision, 
which is currently lacking. The responsibility for ensuring NSP 
is provided in Lithuania falls to a government agency that is not 
supportive of harm reduction approaches. Advocacy for harm 
reduction in Lithuania is strong and the “I Can Live Coalition” is 
actively involved in advocating for harm reduction investment. 
The recent regional Global Fund grant held by EHRN provided 
an opportunity to explore the funding situation in detail and 
to build some capacity for funding advocacy. There is a distinct 
need for continued capacity building in this area to support 
advocacy efforts and to ensure that existing services are 
protected and investment levels increase, or at least are not 
subject to reductions.[32] 
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Transparency of spending data
There is a need for monitoring of harm reduction 
implementation and spending at national level. However, 
without explicit and clear political support and no inclusion 
in national drug policy guidelines, there is no requirement 
to include harm reduction within national monitoring and 
evaluation systems. As a result, expenditure is often hidden in 
general drug service spending records and not disaggregated 
in a way conducive to identifying harm reduction spending. 
Only eight of twenty Italian regions have disaggregated 
spending accounts, which allow some insight into harm 
reduction spending. However, data are not available for all 
years, and are not disaggregated in enough detail to isolate 
NSP-related expenditure. OST spending is embedded in the 
overall spending records of the Public Drug Addiction Units 
within which OST centres are held. The only cost that can 
be isolated is that relating to the medication itself, not its 
provision.[7] 
Differences in harm reduction data gathering between regions 
in Italy pose a challenge to effective national monitoring. There 
are political and methodological steps to be taken to ensure 
the development of national harm reduction guidelines and 
a new data gathering system which explicitly includes harm 
reduction services.[7] 
Government investment in harm reduction
The majority of harm reduction investment in Italy (90-95%) 
comes from public budgets at the regional level which are 
locally held by local health agencies known as ASL. In very 
few cases, harm reduction funding comes in part from 
municipalities (e.g. Venice and Rome) or national private 
donors such as banks or private foundations. Funds from 
the Justice and Social Affairs departments of the European 
Commission contribute to some research, training or 
experimental interventions related to harm reduction, but no 
funds go directly to service provision. 
In 2014, an estimated € 18,892,440 was spent on drop-in harm 
reduction services, including NSP in Italy.n There was a clear 
drop in harm reduction funding and service provision between 
2010 and 2014, when NSP sites decreased from 106 to 72 and 
NSP coverage fell from 24% to 15%.o The few regions where 
harm reduction is more established may have maintained 
stability in their harm reduction budgets during this period, but 
at the national level spending decreased from approximately 
€22,207,000 to €18,892,440.p
In 2014, NSP spending varied dramatically between regions, 
with €3,246,140 spent in Regione Lazio, €1,979,200 spent in 
Regione Emilia Romagna and just €540,000 spent in Regione 
Toscana. Trends in expenditure also differed between regions, 
with Regione Emilia Romagna having stable investment from 
2010 to 2014, Regione Lazio reducing its harm reduction 
budget by about 27% and Regione Toscana increasing it by 
Case study country 
Italy - A snapshot of harm reduction funding 
Research undertaken by Susanna Ronconi 
Harm reduction coverage
People who inject drugs 326,000
NSP Low coverage but huge regional variation – 72 sites reaching about 15% of opioid users in Italy
OST High coverage, 620 OST sites provided OST to 70,699 people in 2014
DCR Not available
Prison harm reduction OST available in all prisons. No NSP in prisons
Take home naloxone National take-home naloxone programme
n This estimate includes the cost of all services provided by the drop-in centres and via outreach, encompassing NSP, take-home naloxone, HIV/HCV testing, social aid, counselling, medical visits and 
first aid.
o Calculated for this project using a denominator of the number of people using opioids problematically, in Ronconi S (2016) Harm reduction works! Research.
p The national spending estimate is based on average yearly spending of 5 NSPs (2 in regione Lazio, 1 in Veneto, 1 Emilia Romagna, 1 Umbria) multiplied by the number of NSPs in Italy, in Ronconi S 
(2016) Harm reduction works! Research.
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8%.q These variations may reflect differences in programme 
need across the regions, but also the political support that 
regional decision-makers had for harm reduction at a time 
when national budgets were being cut in several areas due 
to austerity. As NSP and wider harm reduction services are 
not yet included among the list of essential services (Livelli 
Essenziali di Assistenza, or LEA) that all regions must provide to 
citizens, regional decision-makers can determine the extent to 
which these services are made available.
In 2014, €30,018,724 was spent on pharmaceutical costs 
related to OST (including methadone, buprenorphine, 
naloxone and suboxone).r Isolating spending related to OST 
delivery across the country is very challenging, as this service 
is integrated into the public health system and spending 
that particularly relates to OST delivery, such as staffing and 
infrastructural costs, are not disaggregated. While this project 
could not gather data for the whole country, it was possible to 
gain an insight into OST expenditure and trends over time in 
selected regions.s When delivery costs are considered there 
is some evidence of a reduction in investment since 2010: 
from €147,785,828 to €106,896,888 in 2014. This is due partly 
to cuts to public health funds and partly to a 32% decrease 
in the number of OST clients. Overall, OST remains relatively 
adequately financed, despite the wider public health cuts seen 
in Italy in recent years. In 2014, coverage was estimated to be 
57% compared to 48% in 2010.t OST, unlike NSP and other 
harm reduction services, is included among the LEA that all 
regions must provide to citizens. 
There is no estimate of out-of-pocket harm reduction 
spending, but this is likely to be substantial in one-third of the 
country, where no NSP services exist.
Through their taxes, every Italian citizen 
contributes €0.31 per year towards NSP 
delivery (2014). They also contribute €18.69 
per year to support drug law enforcement 
(covering costs of policing, trials and 
imprisonment).[34] Reaching 100% NSP coverage 
(rather than the current 15%), would cost 
each tax payer €2.07 per year. This cost could 
be covered by shifting just €1.76 from their 
contribution to drug law enforcement and 
repression, over to health and harm reduction.u
At the national level, the government allocates an amount to 
the National Health Fund each year, which includes funding 
for the drug and drug treatment sector. These allocations 
are discussed at the regional level and distributed between 
different sectors according to regional health plans. The drug 
and drug treatment sector is not allocated a fixed percentage. 
Austerity has led to continual cuts to regional health budgets, 
and even those programmes that are included on LEAs may 
receive insufficient funds as a result.v In 2017, there are moves 
to include harm reduction (including NSP) within the LEA which 
will improve the funding situation. In terms of harm reduction 
funding advocacy, it is possible to advocate for harm reduction 
allocations at all the different levels of decision making, but this 
is more feasible and effective at the regional level.[7]
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q Prevention and Treatment Department - Regione Toscana; Drug Addiction Department - Regione Emilia Romagna; Drug Addiction Department - Regione Lazio, in Ronconi S (2016) Harm 
reduction works! Research.
r  Health Institute - Pharmacoepidemiology Department; OsMed annual Reports, in Ronconi S (2016) Harm reduction works! Research.
s  The national spending estimate is based on average yearly spending of 5 OST sites (3 in regione Piemonte, 2 Emilia Romagna) multiplied by the number of OST in Italy, in Ronconi S (2016) Harm 
reduction works! Research.
t  This was calculated using the numerator of the number of people enrolled in OST programmes and the denominator of the estimated number of people using opioids sourced from DPA Annual 
Reports available at http://www.politicheantidroga.gov.it/attivita/pubblicazioni/relazioni-al-parlamento.aspx 
u Calculated by Susanna Ronconi for this project. 
v  Livelli Essenziali di Assistenza are the standard, totally or partially free services guaranteed to all Italian citizens by the National Health System.
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Sustainability of harm reduction funding 
Until 2014, Italian drug laws and policies were particularly 
prohibitionist and did not support harm reduction. The 
National Drug Agency focused on both repression and a rigid 
disease paradigm, alongside a demand reduction approach 
favouring abstinence. While some Italian regions have a long 
history of implementing harm reduction since the mid-
1990s, two-thirds of the regions do not have harm reduction 
guidelines and one-third do not run harm reduction services 
at all. In 2014, the most repressive articles of the drug law 
were abrogated by the Constitutional Court, under pressure 
from civil society. At the same time, staff changes at the new 
National Drug Agency saw the beginning of a change in Italy’s 
approach to drugs. One of the first signs of innovation - 
thanks to coordinated advocacy by civil society organizations, 
professionals and drug user activists – has been the proposal 
to include harm reduction interventions in the LEA. In late 
2016, harm reduction was approved by the Ministers Council 
as part of the new LEA, which in effect, requires all regions to 
implement harm reduction services.w As over 90% of harm 
reduction funds are derived from public sources, this will make 
a significant difference to the sustainability of Italy’s harm 
reduction response. The next step is for the Conferenza delle 
Regioni to develop minimum standards for harm reduction, 
which will be an important moment for national harm 
reduction advocacy.[7] 
Currently, a large proportion of Italy’s NSPs do not have 
the security of stable funding. While some are established 
services, others remain projects which are time-limited with the 
potential to be renewed or have funding discontinued. In 2014, 
one-third (29%) of all harm reduction services (including, but 
not limited to, NSP) were considered stable services, 22% had a 
two-year term, 38% had a 1-2 year term and 11% had less than 
11 months of secured funding.x The projects with the least 
stability are safer nightlife interventions aimed at young people. 
‘In Italy, current drug policy is not investing for 
the future’. Susanna Ronconi, Harm Reduction 
Works! researcher.
The majority of harm reduction service providers in Italy are 
also active harm reduction and drug policy reform advocates. 
There are a small number of networks of people who use 
drugs but they are rarely included in policy-making processes. 
There is a need for renewed and improved opportunities for 
participation of all relevant stakeholders in national and local 
decision-making. There is a need for further evidence of harm 
reduction’s success in reducing HIV and hepatitis C infection, 
as well as preventing overdose in Italy through research, 
monitoring and evaluation. There is also a need for cost-
effectiveness and cost-benefit analyses of harm reduction and 
wider drug policy implementation to inform strategic budget 
allocations at national level.
‘At the municipal level, the harm reduction 
discourse must be developed in order for cities to 
be protagonists of harm reduction as a social and 
community approach, and not only as a health 
policy.’ Susanna Ronconi, Harm Reduction Works! 
researcher
w See DPCM LEA, at http://www.quotidianosanita.it/allegati/allegato5864831.pdf
x  DPA Annual Report 2015 available at http://www.politicheantidroga.gov.it/attivita/pubblicazioni/relazioni-al-parlamento.aspx
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Transparency of spending data
The team assembling the data for this report was not able to 
identify sources of financial data broken down by programme 
within the scope of this project. Dedicated research and 
analysis would be necessary to gain insight into national harm 
reduction spending.[35]
Government investment in harm reduction
Harm reduction investment in Sweden is wholly government 
funded through national health and social budgets. No 
publicly available estimate of spending on either NSP or OST 
programmes was identified for the country. The only published 
data found related to the amount budgeted for HIV prevention 
in 2014, which amounted to approximately €15.3 million,[36] but 
it is not clear what proportion of this went towards preventing 
HIV among people who inject drugs. Harm reduction 
investment is likely to have increased between 2010 and 2014 
to support the establishment of additional NSP and OST sites, 
although there is no spending data available to confirm this.[35] 
Accessing NSP is free in Sweden but coverage is low. In areas 
where NSP is not available, people who inject drugs are 
sometimes able to access injecting equipment from local drug 
users’ unions. However, pharmacies are not permitted to 
sell needles and syringes to people suspected of using them 
to inject illicit drugs. In addition, it is illegal for individuals to 
import needles and syringes into Sweden.[37] OST provision is 
free for people who receive social security support, but others 
are required to pay a maximum fee of approximately €315 per 
year for OST.[35] 
Health care is decentralised to the regional level in Sweden 
which is where most funding allocations for harm reduction 
programmes are determined. While it is decided at the national 
level which interventions are permitted within the country, 
to some extent, harm reduction investment is related to the 
level of political support among decision makers in regional 
government.[35] 
Sustainability of harm reduction funding 
Limited political commitment is the main barrier to sustainable 
harm reduction funding in Sweden. While the current 
government has embraced components of harm reduction 
at the national level more than previous governments, there 
is a concern among harm reduction advocates that elections 
in 2018 could threaten the progress made thus far. Laws 
and policies also pose significant barriers to harm reduction 
implementation. For example, community distribution of 
naloxone is not currently permitted in Sweden as its use is 
limited to emergency services personnel.[35] 
There is a need for investment and capacity strengthening 
in harm reduction advocacy at the national and county level 
in Sweden. This need also extends to calling for necessary 
changes to laws and policies and ensuring that investments 
and the current policy environment is maximised to deliver 
quality services. 
Sweden - A snapshot of harm reduction funding
Harm reduction coverage
People who inject drugs 8,021
NSP Low coverage – 10 sites serving only one-quarter of people who inject drugs
OST High coverage, 159 sites with a reported 3,502 people receiving OST in 2014
DCR No DCRs
Prison harm reduction OST available to those who had been receiving it prior to imprisonment. No NSP in prisons
Take home naloxone Not available, but currently civil society action on this issue
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The Swedish Drug Users Union has carried out important 
harm reduction advocacy alongside academics, but this 
work is severely underfunded. There is currently no national 
platform for harm reduction actors to advocate for increased 
investment or policy change, nor to hold the government 
accountable to national and international commitments. 
Importantly, a harm reduction network is starting to form 
organically and includes key actors from the drug user 
community, academia, policy professionals and service 
providers.[35]
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Transparency of spending data
In the Czech Republic, there are mechanisms in place that 
serve to track some aspects of harm reduction expenditure. 
Through the National Focal Point to the EMCDDA and 
financial reporting of the Government Council for Drug 
Policy Coordination (GCDPC), the spending related to NSP is 
annually tracked. Spending related to OST is more challenging 
to establish as this is not isolated within financial reporting 
and OST is delivered in different settings which report their 
financial expenditure in different ways. Further study was 
recommended and any additional information could bring 
new insight and be used as a basis for better structured, more 
stable funding for harm reduction.[38]
Government investment in harm reduction
Drug policy implementation, of which harm reduction is a part, 
is accounted for in budgets allocated to the Secretariat of the 
GCDPC, the Ministry of Education, the Ministry of Defence, the 
Ministry of Health, the Ministry of Labour and Social Affairs 
and the Ministry of Justice. Projects involving drug services 
also receive financial support from the European Structural 
Funds. Funding for harm reduction initiatives is a significant 
part of drug policy funding overall, but it is not planned, 
budgeted or distributed separately. This makes tracking harm 
reduction-specific funding allocations or spending extremely 
challenging. The exception to this is spending for NSP, which is 
estimated by the National Focal Point for the EMCDDA and by 
the GCDPC. OST service spending, however, is reported within 
a wider package of outpatient services so therefore cannot be 
extracted. 
In 2014, harm reduction was funded mainly from national 
budgets (GCDPC, Ministry of Health & Ministry of Labour and 
Social Affairs) and regional and municipal budgets. Some NSP 
services were also covered partially by public health insurance, 
which was also the main source of funding for OST services. A 
very small proportion of both NSP and OST funding was from 
international donors in 2014. It is estimated that a total of 
€13,415,900 was spent on harm reduction in 2014, covering 
OST and NSP services.y
There are two available estimates of the national investment 
in NSP service provision. The first comes from financial 
reports of the GCDPC which state that €6,497,000 was spent 
on the NSP in 2014. The second is the annual report of the 
Reitox National Focal Point to the EMCDDA which states 
that for 2014, NSP spending from public budgets amounted 
to €7,062,900. It seems more appropriate to use the latter 
estimate because the GCDPC financial reports do not include 
all existing spending. This equates to roughly 58% from 
national government funds and the majority of the rest from 
regions and municipalities, with a very small contribution from 
international donor funds.[38] 
As mentioned, OST provision spending is harder to estimate, 
as this is embedded within wider outpatient service budgets. 
OST programmes are provided within a range of settings 
including state-run and NGO services, both with and without 
contracts with public health insurance companies, separate 
OST programmes or (in most cases) within drug treatment or 
psychiatry outpatients’ services. Financial records from services 
Case study country 
Czech Republic - A snapshot of harm reduction funding 
Research undertaken by Jiri Richter
Harm reduction coverage
People who inject drugs 45,600
NSP Medium coverage – 6.6 million syringes distributed by 105 sites in 2014. Also available to purchase from pharmacies
OST Low coverage – 4,000 clients receiving buprenorphine or methadone in 2014
DCR Not available
Prison harm reduction No NSP. 50 prisoners receiving OST in 2014
Take home naloxone Not available
y  This includes €7,062,900 for NSP and €6,353,000 for OST, in Richter J, SANANIM (2016) Harm Reduction Works! Research.  
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(held centrally by GCDPC) or from public health insurance do 
not disaggregate OST provision costs from those relating to 
other services offered within the same facility. 
Analysis of financial reports from the GCDPC suggests that 
OST provision expenditure reached €471,590 in 2014, of which 
€42,650 was provided from government funds. This estimate 
does not include state facilities, which account for the majority 
of OST provision in the country. A crude calculation using the 
average cost of annual suboxone provision and multiplying this 
by the number of clients in the country produces an estimate 
of €6,353,000, which would have been wholly covered by public 
health insurance in 2014.[38] z
Some drug services receive financial support through 
European Structural Funds (ESF). In the period 2010-2014, 
for example, a total of €3,584,000 was made available for 
programmes intended to facilitate social inclusion and 
employment opportunities for people who use drugs as part 
of three grant calls announced by the Ministry of Labour and 
Social Affairs. It should be noted that all projects funded by ESF 
must be co-financed to the value of 15% by the government. It 
is estimated that between 2009 and 2013, contributions from 
ESF in the total funding of drug treatment services amounted 
to about 12%. It is not possible to determine whether the 
financial resources were used for harm reduction activities. 
In 2014, eighty programmes distributed approximately 200,000 
gelatine capsules for oral methamphetamine use as a harm 
reduction intervention to avoid injecting drug use.[38] 
Experts estimate that between 1-1.5 million needle and 
syringe sets were sold through pharmacies in 2014.[38] With 
the average price of one set being around € 0.10, this would 
equate to a total of between €100,000–150,000 out-of-pocket 
harm reduction expenditure for people who inject drugs in the 
country.[38] 
In addition, most OST clients are required to pay full price 
for their buprenorphine prescriptions, which equates to 
thousands of Czech crowns per month from their personal 
resources. This leads to clients obtaining prescriptions for a 
greater quantity of medicines than needed (a practice known 
as “doctor shopping”), to sell at higher prices on the black 
market as a way of financing doses for themselves.[39] 
The coverage of substitution medicines by health insurance 
remains an issue. Full reimbursement only applies to 
Suboxone, but the eligibility requirements are so restrictive 
that very limited coverage is provided. As of August 2015, 
only four facilities were known to provide treatment with 
reimbursed medication to approximately 75 patients.[38]
Sustainability of harm reduction funding 
In the Czech Republic there is a relatively long history of harm 
reduction implementation, supported by a large network of 
services and professionals including academics. The legal and 
policy framework provides a solid basis for harm reduction to 
receive continued funding in the near future. However, political 
will for harm reduction and national policies might be subject 
to change, as there is no law obligating the provision of these 
services. 
While there has been a small increase in harm reduction 
funding in recent years, there remain gaps in service provision 
that require additional investment. There is a reported a gap of 
€3,676,000 which is required to cover basic operational costs 
of existing NGO services.aa Another €1,838,000 is required 
to increase the coverage and accessibility of OST services 
nationally, NSP in the regions of Prague, the North east and 
North Moravia and to cover the cost of drug consumption 
rooms in Prague.bb
Only a small proportion of the ESFs that the Czech Republic 
receives are likely to be supporting harm reduction, so this 
support could be utilised more fully. Many of the projects 
receiving ESF do not continue as the 15% state contribution is 
challenging to sustain.[38] 
In conclusion, the harm reduction funding situation in the 
Czech Republic is relatively good compared to its close 
neighbours in Europe. However, there is room to improve the 
stability of funding, to increase it to cover service provision 
gaps and increase political support at the regional and local 
level to increase the sustainability of this funding for the future. 
z    This is a crude calculation based on one month Suboxone provision costing 3,600 CZK and provision for one year costing 43,200 multiplied by 4000 (number of estimated clients).
aa   Estimated for this project by subtracting spending estimates from the funding requested for harm reduction in the country. Richter J, SANANIM (2016) Harm Reduction Works! Research.  
bb  Estimated for this project by subtracting spending estimates from the funding requested for harm reduction in the country. Richter J, SANANIM (2016) Harm Reduction Works! Research.
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Transparency of spending data
There are barriers to obtaining a clear understanding 
of harm reduction funding in Portugal. Publicly available 
spending records are scarce, not easily interpreted and do 
not allow a clear understanding of funding of harm reduction 
interventions. In addition, information gathered through 
different sources can be contradictory rendering it difficult 
to establish a true picture of the situation. While there 
was willingness from SICAD (the government department 
responsible for drugs) to share spending information, some 
data are simply not available and the criteria and limits placed 
on harm reduction funding allocations are unclear. 
‘The existence of projects such as ‘Harm Reduction 
Works!’ helps to legitimise enquiries and requests 
for clarification on harm reduction funding. 
This project has already opened doors to solve 
many of these problems in the future since it 
has created the conditions to start a dialogue 
between civil society and government on funding.’ 
Marta Pinto, Harm Reduction Works! researcher, 
Portugal
Government investment in harm reduction
The funding for harm reduction projects, including NSP, is 
managed by SICAD but originally comes from Santa Casa 
da Misericórdia, which is a private organisation that uses a 
proportion of their revenue from social gambling (e.g. from 
‘joker’ or ‘Euromilhões’) to fund some social projects. SICAD 
allocates funding to harm reduction service providers that 
apply for grants. Local government departments responsible 
for drugs also perform regular needs assessments in 
partnership with relevant stakeholders to inform funding 
allocations. According to decision makers and professionals 
interviewed for this project, however, the assessment process 
is not always as participatory as it should be, which may limit 
its accuracy. There are upper limits imposed for applications 
but the reasoning behind the limits remain unclear, for 
example, outreach teams can apply for only €75,000 per year 
and support office applications have a limit of €180,000 per 
year. However, applicants are only eligible for 80% of project 
costs, with the other 20% to be covered by the implementer. 
There is an ongoing civil society effort to allow projects to 
be fully funded by the Santa Casa de Misericórdia. Several 
stakeholders interviewed for this project (decision makers 
and harm reductions professionals) stated that financial 
engineering was a fundamental skill necessary to make the 
best out of their budgets.
In 2015, an estimated €3,330,397 from the Santa Casa de 
Misericórdia funded 40 harm reduction projects.cc There 
has been a scale-up of sites and investment in recent years, 
with 38 projects funded with €3,271,512 in 2014 and only 
31 harm reduction projects operating in 2013 funded with 
€2,042,105.[40]
Case study country 
Portugal - A snapshot of harm reduction funding 
Research undertaken by Marta Pinto
Harm reduction coverage
People who inject drugs 14,426 (12,732-16,101)
NSP Medium coverage
OST High coverage, around 75% of ‘high-risk opioid users’ receiving OST
DCR Not available
Prison harm reduction OST available in all prisons. Pilot NSP in 4 prisons opened in 2007 but were closed after 6 months
Take home naloxone One pilot programme in Braga
cc  The kind of interventions funded as being harm reduction projects in 2014 were: outreach teams (29), low-threshold OST programmes (29), NSP (mostly implemented by outreach teams) (31), 
support offices (harm reduction local services) (6), safer nightlife initiatives (4), shelter centres for people who use drugs (3).
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 In addition, every year approximately €1,000,000 covers 
the cost of syringe distribution through NSP sites including 
pharmacies. Stakeholders note that there is a need for some 
improvements in the materials offered (for example, the 
inclusion of various diameters of needles and tourniquets in 
NSP packs).[41]
The cost of methadone delivery is wholly government 
supported. As OST provision is fully integrated into the 
public health system in Portugal it is not possible to easily 
isolate the costs involved in its delivery, however, some 
insights were gathered on the cost of the medication itself. 
Public expenditure on OST medications amounted to an 
estimated €4,179,571 in 2014, which included methadone, 
buprenorphine and buprenorphine/naloxone, but this estimate 
did not include medication prescribed within hospitals.[42] 
There is no available estimate of out-of-pocket spending 
from people who use drugs on harm reduction. There 
may be significant spending in rural areas where NSP are 
less accessible, but stakeholders also mention a need for 
equipment not currently provided through NSP services, which 
people may purchase themselves.dd
Sustainability of harm reduction funding 
Harm reduction has been somewhat protected from the 
impact of austerity cuts to the health, justice, social security 
and education sectors in Portugal. There is political support 
for the harm reduction approach and the provision of these 
services is considered essential by the current and former 
government. Since funding for low threshold harm reduction 
services comes primarily from a non-governmental source, it 
is simply political will that is necessary to sustain the current 
harm reduction funding levels. However, there is a need to 
make all the available funding for harm reduction accessible to 
ensure this is utilised fully and effectively. 
The economic and financial crisis has had an impact on harm 
reduction workers. There have been funding delays which 
caused some projects to be suspended and others to rely on 
harm reduction workers carrying on delivering services without 
payment. The cost of living has increased but the available 
funds for harm reduction projects have not reflected this, 
making it more difficult to retain staff on reasonable salaries. 
Researchers warn that the quality and availability of services 
are at risk due to the additional pressures on service providers 
and increased risk of staff burnout.[43] 
‘The extra effort of NGO workers in Portugal has 
been crucial to protecting people who use drugs 
from the impact of austerity’ Marta Pinto, Harm 
Reduction Works! researcher
Given the pressures the harm reduction sector is under, it 
is not surprising that most do not have the time to advocate 
for sustainable harm reduction funding. Harm reduction in 
Portugal is being ‘stretched to its limits’ and reaching people 
with services will always remain the priority, to the detriment of 
advocating for change.[41]
dd  For example, needles of greater diameter and aluminium paper to inhale heroin and cocaine base.
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Transparency of spending data
There are multiple organisations (public and private) that 
provide drug-related harm reduction. While the co-operation 
between institutions and organisations is strong, it is 
impossible to estimate the total amount spent on harm 
reduction within the country. There is currently no national 
tracking mechanism that could assist with this calculation. 
Government investment in harm reduction
It is not possible to estimate the total amount of harm 
reduction spending in Finland. In 2014, the total sum spent on 
NSP was estimated to be between €2-2.5 million.[44] Around 
€1.7 million of this was invested in the Helsinki area, which is 
densely populated and where most of the people who inject 
drugs in Finland are situated. This investment was wholly 
covered by government funds.[44]
Similarly, OST provision is covered wholly by government 
funds, but there is no data available on the extent of this 
investment.[44]
Needles and syringes can be purchased without medical 
prescription at most pharmacies in Finland, and pharmacies 
play a key role in needle and syringe provision in areas where 
there are no standalone NSP services. The latest Finnish 
estimate of the amount of needles and syringes sold by 
pharmacies is over a decade old, but at that time, around 
500,000 needles and syringes were sold annually.[44] A needle 
and syringe set is sold for an average of about €2.[44]
Sustainability of harm reduction funding 
Civil society reports that the government is likely to remain 
supportive of harm reduction to current levels in coming years. 
They state that drug policy is not becoming more liberal and 
that law enforcement remains a very prominent feature. They 
lament that an increase in funding would likely only emerge in 
response to an increased public health threat, such as a rise in 
HIV infections among people who inject drugs.[44] 
‘Minimizing harm combined with punitive 
prohibition policy forms a two-pronged paradigm 
for Finland’s drug policy.’ Anne Arponen, A-Clinic 
Foundation, 2016
Access to long-term sustainable funding for harm reduction 
programmes in Finland remains challenging. Additionally since 
2012, funding for HIV prevention in Finland has decreased to 
the extent that there are now reported to be insufficient funds 
available. The impact of this has been more pronounced for 
programmes focusing on men who have sex with men and sex 
workers, than those for people who inject drugs. NSP funding 
in particular has decreased in recent years and the need for 
services has remained unchanged.[44] 
There has been an increasing reliance on competitive 
tendering for service provision in harm reduction and the 
wider HIV sector. This pushes services to provide the same 
service with reduced budgets, which is reported to be affecting 
the quality of services being delivered. Long-term providers 
of harm reduction services are losing bids to new suppliers in 
some areas. 
Finland - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 15,611 (13,770–22,665)
NSP High coverage – 4.5 million syringes distributed in 2014
OST Low coverage – 3,000 clients receiving OST in 2014
DCR Not available
Prison harm reduction OST available in prisons. No NSP available
Take home naloxone No take-home naloxone programmes available
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The services are intended to remain as they were, but changes 
in personnel and location threaten to weaken the trust built 
up between clients and personnel over long periods of service 
provision.
In response to this, the National Institute for Health and 
Welfare will produce guidelines for low threshold service 
centres which will include recommendations on quality, 
consistency and continuity of low threshold harm reduction 
services. The Institute will closely monitor changes of service 
providers and any effects on the quality and continuity of 
services.[44]
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Transparency of spending data
Within this research it was possible to gather spending 
estimates for NSP and OST in 2014 relatively easily due to 
government sources having access to this information and 
their willingness to share data. However, this information 
was not publicly available and had to be requested, and no 
detailed breakdown of spend was shared. As this information 
is collected at the national level, it would be of use to create an 
open access database on national harm reduction spending 
within a pre-existing programme, ‘Statistics Estonia’.[45] 
Government investment in harm reduction
An estimated €2,789,236 covered the full spectrum of harm 
reduction services available in Estonia in 2014.[46] ee This funding 
came in full from the budget of the Ministry of Social Affairs. 
It is estimated that at least €1,160,750 of this was spent on 
NSP in 2014.[47] This does not include the spending of local 
municipalities of Tallinn, Tapa, Kohtla-Järve, Paide, Narva and 
Maardu, from which it was not possible to collect data during 
this research.[45] 
Approximately €1,040,968 of this funding went towards OST 
provision in 2014,[47] with €17,153 estimated to have been 
spent on overdose prevention and naloxone distribution.[48] 
The benefit of this investment was quickly evident. The number 
of reported overdoses steadily decreased following the 
implementation of the take-home naloxone programme, from 
170 overdose deaths in 2012 (before the THN programme 
started), to 84 overdose deaths in 2015.[47] 
Under the National Health Plan 2009 – 2020 in Estonia, there 
are shorter term implementation plans with attached budgets 
which include harm reduction allocations. The budget is held 
by the Ministry of Social Affairs, but it is the National Institute 
of Health Development (NIHD) that is responsible for the 
distribution of these funds among service providers. The NIHD 
draws up contracts directly with service providers and local 
municipalities who provide the harm reduction services, or in 
some cases there are tripartite agreements between the NIHD, 
the local municipality and the service provider.[45]
Sustainability of harm reduction funding 
Harm reduction funding in Estonia is considered to be 
sustainable in the near future assuming there are no major 
shifts in the Estonian political landscape. Following the retreat 
of the Global Fund in 2007, the government of Estonia began 
fully financing the national harm reduction programme. The 
government has now been consistently investing in harm 
reduction approaches for over a decade and even maintained 
this investment following the economic crisis in 2008. It is 
encouraging that harm reduction continues to be emphasised 
in national health and drug strategies, plans and policies.[46, 49]
There are, however, some gaps in current service provision 
where an increase in investment would be valuable. The 
NIHD highlighted some immediate gaps to be addressed in 
current harm reduction provision in Estonia. These include the 
integration of harm reduction, health and social care services 
for people who inject drugs; linking the services with the 
prison and detention system; ensuring an appropriate range 
Case study country 
Estonia - A snapshot of harm reduction funding 
Research undertaken by Jaan Väärt
Harm reduction coverage
People who inject drugs 5,362 (3,906 - 9,837) 
NSP High coverage - 36 sites reached approximately 6,305 people in 2014
OST Low coverage - 8 sites with 919 clients in 2014 receiving methadone
DCR Not available
Prison harm reduction OST is available. Naloxone distribution available in 3 or 4 prisons. No NSP
Take home naloxone 733 take-home naloxone kits distributed in 2014
ee  This included funding for NSP, overdose prevention, STI diagnostics and treatment services for people who inject drugs, OST, sexual behaviour counselling for youth with health insurance, STI 
diagnostics and treatment services for women involved in sex-work, provision of infant nutrition for HIV-positive mothers, voluntary counselling and testing service, case-management for people 
living with HIV, specialist training and services within prisons.
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of easily accessible services and improving the geographical 
coverage of services.[50] Service providers interviewed for this 
project stated that there was a need for regular needle and 
syringe programmes to be provided in the areas of Paldiski, 
Pärnu, Tartu and Jõgeva and the need for OST provision in 
Maardu City. They also noted that sterile water is not currently 
available for distribution.[45] In addition, hepatitis C treatment 
is not currently guaranteed for people who do not hold health 
insurance.[45] The NIDH also raised the lack of access to sterile 
injecting equipment in prisons and the need to strengthen 
data collection. Furthermore, the salary level of people 
working in the harm reduction sector is not motivating. A harm 
reduction worker at NGO Convictus, for example, receives 
a salary equal to 60%-70% of the national average wage in 
Estonia.[45]
In addition to increased funding, solidifying the legal status of 
harm reduction by defining and including it in legislation was 
highlighted as a valuable step that could be taken in Estonia.[45] 
Harm reduction currently exists ‘in a no-man’s land’ between 
medical and social services. Legislative clarity would provide a 
more solid basis for the provision of the service and perhaps 
be a step towards changing legislation to allow NGOs to carry 
out HIV rapid testing and to provide OST.[45] 
There is not currently an active harm reduction advocacy 
movement in Estonia to protect the interests of people who 
use drugs and call for improved harm reduction investment 
from the government. In late 2016, the first Estonian 
association of people who use psychotropic substances was 
officially registered as an NGO.
‘Relatively good state funding of harm reduction 
has led to a situation in which NGOs and other 
service providers have become contractors whose 
work is defined by the government rather than 
the needs of people who use drugs. Fortunately, 
in general those two have so far overlapped.’ Jaan 
Väärt, Harm Reduction Works! researcher 
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Transparency of spending data
Spending on harm reduction programmes is not centrally 
tracked so there is no repository of information on what is 
being implemented or spent across the UK. In order to gain 
insight into harm reduction expenditure in the UK, spending 
records would have to be accessed at the local level from 
commissioning groups and then be aggregated. Civil society 
respondents recognised this as a problem and emphasised the 
need to track this investment and the implications of recent 
funding changes. They highlighted a need to centrally track 
NSP service closures as well as the extent to which naloxone is 
being distributed and to whom. 
Government investment in harm reduction
Harm reduction is predominantly funded by the government 
in the UK, with the exception of some established harm 
reduction service providers supplementing their funding with 
small grants from donors such as Big Lottery and the Amy 
Winehouse Foundation. In 2013/14, budget decision-making 
for harm reduction and drug treatment in England and Wales 
shifted from national Government to local commissioning 
groups. These groups decide where to allocate public health 
funds for their area. 
The metrics of success for drug services in England are centred 
on ‘recovery’ and becoming ‘drug-free’. As a result, they are not 
rewarded for providing harm reduction but instead for helping 
clients to cease drug use and to reduce or end their OST 
prescriptions. In some areas commissioners have introduced a 
payment-by-results model with enhanced payment being given 
based on numbers of people exiting treatment ‘drug free’, 
ultimately leading to a focus on abstinence at the expense of 
harm reduction. Civil society reports that this makes it difficult 
for service providers to prioritise clients that are less likely to 
become drug-free as quickly or easily as others. There are also 
reports of clients being pressured to reduce OST dosages, 
to engage in other interventions in order to receive an OST 
prescription, and an overreliance on daily pick-ups even where 
clients had previously had take-home provision.[51] 
NSP services have also been affected by recent funding cuts, 
with a number of drop-in sites closing and others being 
forced to streamline their services.[52] Provision is increasingly 
pharmacy-based in England. Pharmacies receive financial 
incentives to provide safer injecting kits, but they rarely offer a 
service comparable to that of a dedicated harm reduction site, 
where trained staff deliver advice tailored to client needs and 
provide referrals to other health, social and welfare services 
not offered on site. Standalone services that remain are 
streamlining their services in some areas, by way of reducing 
staff training, hiring staff on zero-hours contracts and reduced 
pay, and limiting the kits being distributed. At a time when 
harm reduction should be intensified to respond to the highest 
rates of drug-related deaths ever recorded in the UK, there is a 
disinvestment in harm reduction.[52]
UK - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 122,894 (117,370-131,869)
NSP High coverage 
OST High coverage, including limited prescription of heroin-assisted treatment
DCR No DCRs yet, but a planned supervised injecting facility in Scotland
Prison harm reduction OST available in all prisons. No NSP in prisons
Take home naloxone National take-home naloxone programme in Scotland
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Sustainability of harm reduction funding 
Civil society anticipates further reductions in harm reduction 
funding in England in the coming years. In 2018, funding for 
harm reduction programmes will no longer be protected within 
local public health budgets, which could result in funding cuts 
in areas where local commissioning bodies do not prioritise 
these services. There is an increasing tendency for services 
to be delivered by third sector organisations competing 
for contracts through a tendering process. Civil society 
predicts that these factors will likely lead to reduced training 
and staffing levels and in the commodities and equipment 
provided, thus compromising the quality and capacity of those 
services still running. There is a fear that this will lead to rises in 
HIV and hepatitis C incidence among people who inject drugs, 
as well as an increased burden on emergency services. They 
highlight the need for stronger harm reduction advocacy in the 
UK to call for sustainable harm reduction services.[51, 52]
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Transparency of spending data
While there is a mechanism in place to monitor national 
drug policy expenditure, costs relating to harm reduction 
interventions are not disaggregated from the wider labelled 
health spending. As NGOs provide most harm reduction 
services, usually alongside a wider array of drug services, 
it would require dedicated research to establish current 
spending on harm reduction. 
‘While NGOs are leaders in advocacy work, the 
way in which government departments and 
agencies present their budget figures makes it very 
difficult for NGOs to carry out detailed cost benefit 
analysis in relation to harm reduction services. 
NGOs do not generally have access to the levels of 
specialist expertise required to drill in to the detail 
of state funding and to carry out these financial 
calculations’ Anna Quigley, Citywide Drugs Crisis 
Campaign
Government investment in harm reduction
The Government Department of Health is the primary source 
of harm reduction funding in Ireland. There is no available 
estimate on government investment in NSP delivery. This 
investment has been supplemented by an Elton John AIDS 
Foundation of around €750,000 which has been used to 
facilitate the implementation of the national pharmacy needle 
and syringe programme since 2011, in partnership with the 
Government Health Service Executive. 
Civil society estimates that Government spending on OST 
provision was approximately €19 million in 2014. The cost of 
OST provision per client is likely to be higher in Dublin than 
elsewhere in Ireland, reflecting higher levels of clinical support 
available in the city.[53] 
The national drugs budget is determined at the national level 
and allocations to service providers are made at the local 
level by the Health Service Executive and through Drugs Task 
Forces. Civil society report that harm reduction and wider 
drugs services are not adequately funded, with austerity 
measures leading to budget cuts of up to 30% since 2008. 
EMCDDA report that drug-related expenditure overall has 
reduced by 16% since 2009.[54] These funding reductions have 
made it increasingly difficult to maintain existing service levels 
and to allow service providers to engage in essential harm 
reduction advocacy.[53] 
It is not possible to establish what proportion of drug-
related expenditure goes towards harm reduction initiatives 
in Ireland. In 2015, 51.7 % of the planned budget was 
allocated to activities falling with ‘health’ but this would have 
encompassed harm reduction alongside a wide range of other 
health interventions. Just over one-quarter of the budget was 
allocated for public order and safety, which would include drug 
law enforcement. In 2014, the total drug-related expenditure 
amounted to 0.12 % of gross domestic product in Ireland. 
Ireland - A snapshot of harm reduction funding 
Harm reduction coverageff
People who inject drugs 6,289 (4,694–7,884) 
NSP No data available
OST Likely high coverage, with 9,764 people receiving methadone in 2014
DCR No DCRs yet, but a planned supervised injecting facility to open in 2017
Prison harm reduction OST available in 11 out of 14 prisons, with a total of 524 prisoners on OST in 2013. No NSP in prisons
Take home naloxone Pilot take-home naloxone project is underway
ff  It was not possible to ascertain coverage levels of NSP in Ireland as data were not available.
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Sustainability of harm reduction funding 
National policy in Ireland includes a commitment to a public 
health approach to drugs and there has been a specific 
commitment from Government to provide for the introduction 
of a pilot supervised injecting facility in 2017. As a new National 
Drugs Strategy is currently being drafted, continued lobbying 
and campaigns will be necessary to ensure that plans come to 
fruition. Civil society-led campaigns have been at the forefront 
of harm reduction developments in Ireland, for example in 
securing legislative change to allow for supervised injecting 
facilities, and in the national expansion of NSP services.[53] 
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Transparency of spending data
There are many challenges to establishing harm reduction 
investment in Belgium, both in the Flemish and French 
communities. Funding comes from both the national and 
regional budgets, and spend is not disaggregated in a manner 
conducive to tracking harm reduction spending. 
Government investment in harm reduction
Harm reduction is fully government funded in Belgium but this 
funding comes from the national level and city-level budgets. 
Both in the Flemish and French parts of the country, NSP 
services are wholly funded by the respective government 
departments. In 2014, this investment was an estimated 
€560,000 within the Flemish part of the country.[55] There is 
no estimate available for the equivalent spending within the 
French part of Belgium. Across the country, funds come from 
both the national government and city-level investment which 
makes it challenging to gain a complete picture of national 
spending on harm reduction. In order to access funds for harm 
reduction delivery, NGOs must apply to the government with a 
proposal and budget. If granted and the project is established 
and is successful in achieving good results, NGOs may be able 
to access structural funding. 
Across the country, OST is funded through social security. It 
is not free at the point of delivery, requiring clients to pay a 
charge for medication of around €3.50 per week. Civil society 
also reports that people regularly buy their own sterile injecting 
equipment, even where they have the option to access them 
for free from NSP sites, so some investment in harm reduction 
comes from people who use drugs themselves. 
Civil society representatives report that there has been a slight 
increase in harm reduction investment in recent years, but that 
some gaps remain in the harm reduction response for which 
additional funding would be required. For example some parts 
of the country do not have adequate coverage of NSP services. 
Furthermore, there are not currently any NSP programmes 
within prisons in Belgium.
Sustainability of harm reduction funding 
The biggest barrier for sustainable funding for harm reduction 
in Belgium is the moralistic view attached to drug use held by 
the majority of the public and government alike. This results 
in harm reduction not being as mainstream and accepted as 
it should be. The government favours abstinence over harm 
reduction, and law enforcement over support in its drug policy. 
This is reflected in the findings of an assessment of drug policy 
expenditure in 2012, which showed that harm reduction 
spending represented only 0.3%, treatment (including OST and 
abstinence based treatment) represented 29.9% and drug law 
enforcement an overwhelming 68.8% of national drug policy 
spending. Overall, drug policy expenditure represented 0.16 % 
of gross domestic product (GDP) in 2012.[56] 
Belgiumgg - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 25,295 (17,638–35,699)
NSP Unknown because pharmacy NSP distribution figures not available, but national coverage likely to be moderate 
OST High coverage – 17,026 clients receiving OST in 2014, including some receiving heroin-assisted treatment
DCR Not available
Prison harm reduction OST available in prisons. No NSP available
Take home naloxone No take-home naloxone programmes available, but civil society hoping to start one in 2017
gg  HRI received a civil society survey response on the Flemish community in Belgium, not the French community or the German community and this is reflected in this section. 
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Civil society in the country reports that funding for harm 
reduction is sustainable in the short term with funding levels 
likely to remain at existing levels for NSP and OST. They report 
however that the government is less likely to fund new and 
innovative harm reduction approaches. 
In 2015, an initiative to support people who use drugs 
that have tested positive for hepatitis C and either wish to 
access treatment or are currently receiving treatment began 
in Antwerp. Known as the ‘CBuddy peer project’, this was 
originally funded by pharmaceutical companies, but in early 
2017 the Flemish government began to cover the costs of this 
initiative.[55] 
Civil society organisations have a strong history of harm 
reduction advocacy in Belgium, but they are not currently 
involved in advocacy on harm reduction funding and note that 
there is a need for increased capacity in this area. 
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Transparency of spending data
Some spending information on harm reduction is publicly 
available in France. For example, civil society were able to 
access estimates of national spending on NSP and OST 
programmes. The biggest challenge in gathering data on harm 
reduction is to disaggregate funds that have been allocated 
to addictology centres, which provide a range of drug-related 
services, to have a clear sense of the budget specifically 
dedicated to harm reduction activities.[57] 
Government investment in harm reduction
A three-year National Drug Action plan and associated budget 
determines part of the funding allocations for harm reduction 
funding in France. The social security system provides a stable 
source of funding for harm reduction which covers 80% of NSP 
delivery and 90% of costs involved in OST provision. At the local 
level, Regional Health Agencies determine how to distribute 
allocations to service providers. The remaining funding for 
harm reduction is covered by local public entities such as 
regional councils and municipalities. This funding usually 
covers specific programmes such as outreach in rural areas or 
safer nightlife interventions. 
Civil society report that €200-230 million was spent on harm 
reduction measures in 2014. This figure includes €32 million 
for low threshold drop-in centres, €150 million for OST 
(including consultation, medicine and structural costs) and 
€45 million for NSP (including outreach).[58] The new drug 
consumption room that opened in late 2016 in Paris has a 
budget of €1 million per year, which will be covered entirely by 
the social security system. According to civil society, funding 
for harm reduction increased between 2010-2014, with extra 
monies covering increases in the number of drop-in centres 
and NSP sites. In their view, government support for these 
programmes was forthcoming as a result of the positive impact 
of these programmes in reducing drug-related deaths and 
reducing HIV infections among people who inject drugs. Unlike 
several other countries in the European Union, it is reported 
that out-of-pocket harm reduction expenses by people using 
drugs are minimal, as most services and commodities are 
available free of charge. 
Interestingly, in France one-tenth of money coming from 
police seizures is allocated to drug prevention and care, 
which includes harm reduction. This is coordinated by the 
Inter-ministerial Mission of Drugs and Addictive Behaviours, 
which makes allocations to programmes directly. In 2016, it 
is reported that in total this amounted to €1.14 million but it 
is not clear what proportion was allocated to harm reduction 
programmes.[57]
EMCCDA report that total drug-related expenditure in 
2013 was equivalent to 0.1 % of gross domestic product 
(approximately €2 billion). Of this, the majority (44.6%) 
went to health activities and social protection, while 28.6% 
went towards public order and safety with the rest going to 
education, drug-related defence initiatives and general public 
services.[59]
France - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 122,000 
NSP Likely high coverage – 583 sites with estimated 90,000 people using them
OST High coverage, 161,388 clients were prescribed OST in 2014
DCR One DCR in Paris and one in Strasbourg
Prison harm reduction OST available in all prisons. No NSP in prisons
Take home naloxone No national programme. Limited to prescription by a doctor only
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Sustainability of harm reduction funding 
Civil society are optimistic that the government has the ability 
and willingness to sustain harm reduction funding levels in 
the next five years but they note that this will depend on the 
incoming government’s approach to drugs.[57] Already there 
are plans to implement further DCRs in France as part of a six 
year trial. There are also plans for a new ‘take-home naloxone’ 
programme for which funding is expected to be secure. 
Harm reduction advocacy is strong in France, with NGOs and 
associations working in partnership to call for change. This has 
included advocacy for the establishment of a DCR, and ongoing 
efforts to allow hepatitis C treatment to be covered by social 
security funding. They note that a major focus of their advocacy 
is simply ensuring that policies and plans made by decision-
makers are adequately funded and implemented, so that 
‘acts and budgets follow words’.[57] However, ideology and the 
repressive drug laws and policies continue to hamper advocacy 
efforts. For example, the law criminalising the use and 
promotion of use of drugs was a barrier to the government 
agreeing to fund the DCR.[57] 
‘Harm reduction will not be completely effective as 
long as we keep repressing rather than regulating 
drug use’. Laurene Collard, Federation Addiction, 
France 
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Transparency of spending data
There is no central collection of spending information on any 
aspect of harm reduction programming in Germany. To gain 
insight into national expenditure, this would need to be tracked 
at the state, or Länder (local district) level and collated. This 
would also apply to collecting spending information on harm 
reduction in prisons, which again falls under the responsibility 
of the Länder.
Government investment in harm reduction
Harm reduction in Germany is wholly funded by the 
government at the state and municipal level, which is also 
where decision-making on funding allocations occurs. Harm 
reduction funding is reported to have reduced between 
2010-2014, as reduced allocations have been made available 
to municipalities and Länder. This is reported to be due to 
competing government priorities and obligations, for example, 
costs relating to the German response to the refugee crisis. As 
in other countries, civil society are the main providers of harm 
reduction services and they receive funds from the Länder to 
implement services. 
While no information is readily accessible on drug law 
enforcement spending, a study of the EMCDDA’s Reitox Focal 
Point in Germany some years ago reported the ratio between 
’Repression – Help’ to be 7:3.[60]
Sustainability of harm reduction funding 
The German government has a long history of supporting 
harm reduction domestically and overseas via the German 
Society for International Cooperation (GIZ). Civil society report 
that the government is likely to have the capacity and political 
will to sustain their investment in harm reduction for the next 
five years. 
Germany - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 94,250 (56,000–169,500)
NSP Likely high coverage, particularly in the North and West of the country
OST High coverage – 77,500 clients in 2014
DCR 24 DCRs operating in 15 cities
Prison harm reduction OST available to prisoners but currently reaches only 10-15% of those who could benefit from it. One women’s prison has NSP
Take home naloxone No take-home naloxone programmes available
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Transparency of spending data
Isolating spending related to harm reduction in the 
Netherlands would be an extremely difficult task, as harm 
reduction funding is embedded in federal budgets, research 
budgets, municipal budgets as well as being covered by health 
insurance. NSP, for example, is included in municipal budgets, 
whereas OST is covered by health insurance. While national 
civil society recognised the value that tracking this information 
would bring, they highlighted that it would be challenging.
Government investment in harm reduction
Civil society respondents were unable to provide any 
information on the financial investment of the government into 
harm reduction in the Netherlands, for reasons outlined above. 
However, they note that the level of funding has remained 
stable in recent years and quality and coverage of harm 
reduction services is sufficient.[61, 62]
In 2003, it was estimated that harm reduction represented 
10% of drug-related expenditure in the Netherlands and 
with three-quarters of overall spending attributed to law 
enforcement. Treatment (including OST) and prevention were 
allocated 13% and 2% respectively. Overall, drug-related 
expenditure at the time of the study represented 0.5% of gross 
domestic product in the Netherlands.[63]
Sustainability of harm reduction funding 
Harm reduction remains an integral part of Dutch national 
and international drug policy, and as such, it is anticipated that 
funding for harm reduction will continue at current levels for 
the foreseeable future.[62] However, is it noted that spending 
in relation to public health care in general is under pressure. 
Consistently high coverage of harm reduction programmes for 
several decades has been credited for the low rates of drug-
related harms in the country. As a result, responding to drug 
use is no longer an urgent political priority, therefore on-going 
advocacy to serve as a reminder of the benefits of a public 
health response to drugs will continue to be necessary.[61]   
The Netherlands - A snapshot of harm reduction funding 
Harm reduction coverage
People who inject drugs 2,390 (2,336–2,444) 
NSP High coverage – 175 sites
OST High coverage, with 7,569 people receiving methadone and 697 receiving heroin assisted treatment in 2014. No estimate for the number of people receiving buprenorphine
DCR 31 DCRs each seeing about 50 visitors per day
Prison harm reduction OST available in all prisons. No NSP in prisons
Take home naloxone May be available from one or two DCRs, but no nationwide programme in place
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Europe is the birthplace of harm reduction, and the region where the successes of this approach in averting 
epidemics can be most plainly seen. It includes harm reduction champion countries, that have long invested 
in their national harm reduction programmes and implement a wide array of interventions. However, austerity, 
international donor retreat and poor political support are severely limiting harm reduction responses in several 
countries in the EU. In some states, there is a funding crisis for harm reduction which must be addressed if public 
health emergencies are to be avoided.
 
This report summarises research findings from Harm Reduction Works!, providing a snapshot of harm reduction 
investment in eighteen EU member states. It includes findings from spend tracking research in the Czech Republic, 
Greece, Italy, Estonia, Portugal, Hungary and Lithuania. Using a simple traffic light system, countries are categorised as 
either red, amber or green on four criterion, providing an at-a-glance indication of the health of harm reduction funding 
in a country. The report provides recommended actions to increase the sustainability of harm reduction funding within 
the European Union.
Harm Reduction International is an international non-governmental organisation that works to reduce 
drug-related harms by promoting evidence-based public health policy and practices, and human 
rights based approaches to drug policy through an integrated programme of research, analysis, 
advocacy and civil society strengthening. Our vision is a world in which individuals and communities 
benefit from drug laws, policies and practices that promote health, dignity and human rights.
